Lequembi was approved with CDR-SB as primary endpoints and ADAS-Cog 14 and ADCS-MCI-ADL these scales are better than -Cog13 and ADCDS-ADL for a population that was almost entirely MCI.
Donanemab was approved using the iADRS scale (Which is a combination of ADAS-Cog 13 and ADCS-iADL).
I need to make a small correction to my previous post. The four studies totaled ~900 patients...not 1200. (Still considered to be very significant, IMO)
Again, you should pay close attention to the end of the video starting at the 18-minute and especially the 21-minute mark. THIS is why I believe there was so much insider buying.
The combined data from all four studies (which is around 900 patients) compared to the SOC (as shown on the chart) is very impressive.
Market Data 
Markets 
AI
